Therapy for Myeloproliferative Neoplasms: When, Which Agent and How?

Holly L. Geyer, M.D
Geyer.holly@mayo.edu

Ruben A. Mesa, M.D
Mesa.ruben@mayo.edu

1 Division of Hospital Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA
2 Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona, USA

All Correspondence:

Ruben A. Mesa, M.D.
Professor of Medicine
Division of Hematology and Oncology
Mayo Clinic
13400 E Shea Blvd
Scottsdale, AZ, USA
85259
Telephone: 480-301-4502
Fax: 480-301-4675
Mesa.ruben@mayo.edu

Keywords: essential thrombocythemia; polycythemia vera; myelofibrosis; primary myelofibrosis; myeloproliferative neoplasms; JAK2 inhibitors
Abstract

Myeloproliferative neoplasms including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (primary myelofibrosis [PMF] and secondary MF [Post-ET/PV MF] are recognized for their burdensome symptom profiles, life-threatening complications and risk of progression to acute leukemia. Recent advancements in our ability to diagnose and prognosticate these clonal malignancies have paralleled the development of MPN-targeted therapies which have had a significant impact on disease burden and quality of life. Ruxolitinib has shown success in alleviating the symptomatic burden, reducing splenomegaly and improving quality of life in patients with MF. The role and clinical expectations of JAK2 inhibition continues to expand to a variety of investigational arenas. Clinical trials for patients with MF focus on new JAK inhibitors with potentially less myelosuppression (pacritinib) or even activity for anemia (momelotinib). Further efforts focus on combination trials (including a JAK inhibitor base) or targeting new pathways (i.e. telomerase). Similarly, therapy for PV continues to evolve with phase III trials investigating optimal front-line therapy (hydroxyurea or interferon) as well as second line therapy for hydroxyurea refractory or intolerant PV with JAK inhibitors. In this article, we examine the evolving data and role of JAK inhibition (alone or in combination) in the management of patients with MPNs.
Introduction

The classic \textit{BCR-ABL1} negative myeloproliferative neoplasms include polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (primary myelofibrosis [PMF] and secondary MF [Post-ET/PV MF].\textsuperscript{1} ET and PV are characterized by increased platelet counts and erythrocyte counts, respectively, a heightened risk of thrombotic disease, microvascular symptoms and survival rates which can approach those of the general population. MF, however, is traditionally a more problematic neoplasm with a frequently debilitating symptom profile that includes constitutional symptoms, splenomegaly, cytopenias, extramedullary hematopoiesis, risk of leukemic transformation (i.e. MPN blast phase) and decreased life expectancy.\textsuperscript{2} Given the heterogeneous clinical needs of MPN patients, determination of when to treat, which agents to employ and how best to utilize them is often difficult. We examine the recent advances in assessing symptoms and prognosis, as well as risk-based treatment strategies.

\textbf{When to Treat?}

\textit{New MPN Molecular Insights}

Management of patients with MPNs has evolved concurrently with our understanding of the molecular pathogenesis of these disorders. In 2005, the \textit{JAK2V617F} mutation was found to be present in 95\% of PV patients, 65\% of PMF patients and 55\% of ET patients.\textsuperscript{3} A variety of other mutations such as \textit{JAK2 exon 12, MPL, IZF1, TP53, TET2, ASXL1, IDH1/2 and EZH2} also are believed to play a role in the pathogenesis of MPN disorders with some potentially facilitating clonal section and promoting dominance of the \textit{JAK2V617F} subclone.\textsuperscript{4-9} Many of these genes function in epigenetic regulation and often precede the JAK2 mutation, suggesting that
development of MPN disorders is the result of combined genetic deregulation as opposed to a single-hit mutation. In 2013, mutations in \textit{CALR} (calreticulin) were reported to be prevalent in ET and PMF patients with non-mutated \textit{JAK2} or \textit{MPL}.\textsuperscript{10,11} In a large study of 274 PMF patients, \textit{CALR} mutated patients had improved overall survival at a median of 20.2 years vs. 8.2 years in wild-type patients.\textsuperscript{12} Recently, \textit{CALR-ASXL1}+ mutational status was noted to be an important risk factor for survival in PMF (HR 3.7 vs. 2.8).\textsuperscript{13} Whether the survival benefit is restricted to specific \textit{CALR} subclones remains under investigation.\textsuperscript{14} In ET and PV, the \textit{CALR} mutation is also associated with a decreased incidence of thrombosis and leukemic transformation.\textsuperscript{15,16} There is emerging data suggesting \textit{CALR} mutated patients may respond in a uniquely positive manner to therapies, particularly ET patients receiving interferon-alpha (IFN\textalpha{}).\textsuperscript{17} In general, triple negative patients (\textit{JAK2V617F, CALR, MPL}) demonstrate inferior survival to those carrying the mutations.\textsuperscript{18} Despite our advances, the true role of molecular status in choice of MPN therapy is evolving and requires further validation before routine application.

\textit{MPN Symptom Burden}

MPN patients can be highly symptomatic regardless of their subset of disease. Evidence supporting the role of symptoms in the diminution of both quality of life and life expectancy is substantial.\textsuperscript{19} MPN-specific patient reported outcome tools (MPN-SAF\textsuperscript{20} and MPN 10\textsuperscript{21}) have identified fatigue (87\%), concentration problems (62\%), early satiety (61\%), inactivity (61\%), night-sweats (53\%), itching (53\%), abdominal discomfort (52\%), bone pain (48\%), weight loss (34\%) and fevers (19\%) to be prevalent and inadequately managed disease attributes (Figure 1, Figure 2 Panels A and B).\textsuperscript{20,21} Symptoms are prominent in low risk MPN populations as well. In a recent study assessing symptom burden response thresholds, it was noted that low risk MF (DIPSS),
PV (Tefferi criteria) and ET (IPSET) patients were moderately to highly symptomatic in 44%, 50% and 41% of cases, respectively.22

**MPN Prognostic Assessment**

As stated, disease complications are a leading source of morbidity and mortality within the MPN disorders and play an important role in determining when to initiate therapy. Major thrombotic events range from 10-29% for ET and 34-39% for PV.23 Hemorrhagic events are slightly less prevalent and both issues contribute to premature mortality. PV and ET remain at risk for transformation to MF and ensue a similar course to PMF in terms of symptoms, disease complications and prognosis.24 Transformation to acute myelogenous leukemia (AML) occurs most frequently in MF, followed by PV and ET. Once AML conversion has occurred, the median survival is 2.6-5 months.25 Prognostic tools have been developed for each of the MPN subtypes (Table 1). In ET, the International Prognostic Score for ET (IPSET) has been validated to predict survival and the occurrence of thrombosis.26 For PV, the prognostic algorithm developed by Tefferi and colleagues in 2013 remains the most widely employed.27 For MF, the main data exists for prognosis for those with primary myelofibrosis. Prognosis may be estimated using the International Prognostic Scoring System (IPSS) at the time of diagnosis or the Dynamic International Prognostic Scoring System (DIPPS) at any time during the disease process.28,29 An updated ‘DIPSS-PLUS’ algorithm incorporates other independent risk factors including red cell transfusion requirements, thrombocytopenia and unfavorable karyotypes.2 As previously discussed, insights into the prognostic impact of CALR-ASXL+ status will likely result in their inclusion within DIPSS-PLUS assessment. Recognizing that symptom burden frequently contrasts that expected for patients given risk status, a recent study explored symptom heterogeneity between risk score categories in MPN disorders (Figure 2 Panels A and B). A detailed analysis of this
heterogeneity identified that unique phenotypic clusters are present within MPN disorders and may not be superimposed as surrogates for prognostic evaluations. The study also demonstrated that significant symptom burden is present within in lower risk MPN populations who, until recently, have only been candidates only for conventional, non-targeted treatments.

Current Guidelines for Timing of MPN Therapy

The 2011 European Leukemia network (ELN) treatment recommendations were among the first evidence-based MPN treatment algorithms to address the timeline and order of therapeutic interventions. Recognizing that the life expectancy in ET and PV may not be diminished in select populations, the primary goals of therapy for both PV and ET include prevention of thrombotic and bleeding complications in addition to minimizing the risk of progression to MF or acute leukemia. In contrast, MF treatment goals are based on assessment of both disease burden (symptoms, cytopenias, splenomegaly) and impact of disease on survival. It is important that the physician discuss the short and long-term goals with the patient, covering potential sources of morbidity and impact on life expectancy. Details regarding the selection of appropriate therapies are discussed below.

Which Agents to Use

Following discovery of the JAK2 mutation, numerous targeted therapies have entered testing for MPN patients. Treatment options for MPN patients can be best divided into the categories of observation, medical therapies, and allogeneic stem cell transplantation. Medical therapies themselves fall into categories of cytoreductive
agents, single agent JAK inhibitors, combination approaches with a JAK inhibitor base, and non-JAK targeted agents. Successful management of MPN patients along their disease course may employ several of these approaches alone or in sequence.

Allogeneic Stem Cell Transplant for MPNs

Allogeneic stem cell transplant (allo-SCT) is the only curative option for MF patients and is typically reserved for patients whose life expectancy is under 5 years. This includes DIPSS intermediate-2 and high-risk individuals, along with patients with unfavorable cytogenetic abnormalities who are considered appropriate candidates in terms of their comorbidities and physiologic age. Overall survival is 50% for patients receiving conventional-intensity conditioning and life expectancy may be less than that expected if the patient did not undergo transplantation. Prospective, randomized studies specifically investigating features of the optimal allo-SCT candidate are lacking. Given the risks of graft failure, graft vs. host disease and regimen-related toxicities associated with the procedure, physicians must consider the numerous factors that may affect outcome including a patient’s baseline red blood cell (RBC) transfusion load, age, HLA donor status and availability. There is a great deal of complexity associated with allo-SCT’s in MF. As such, management of the disease begins with placing patients in a category of ‘urgent’, ‘delayed’, or ‘never’ in regards to the timing of a transplant (Figure 4). Whether new therapies, such as JAK2 inhibitors, impact decision making for transplant remains to be seen but might first impact those in whom allo-SCT has already been selected.

Aspirin, Phlebotomy and Cytoreductive Medicine for MPN Management

Low dose aspirin for the prevention of vascular events has been evaluated in both PV and ET. For PV patients, the ECLAP study clearly demonstrated a reduced risk
of vascular events without significantly increasing bleeding risk. Thus it remains first line therapy for all PV patients regardless of risk score, provided there are no absolute contraindications. The role of aspirin in ET is less clear in low-risk patients outside of the presence of microvascular symptoms. Evidence supporting the role of phlebotomy in all PV patients with hematocrit levels >45% was proven in the CYTO-PV trial where patients with controlled hematocrits had significantly reduced cardiovascular deaths or major thrombosis in comparison to more liberal hematocrit levels.

Cytoreductive therapy is frequently employed in high-risk PV and ET patients to reduce the occurrence of thrombohemorrhagic events and treatment decisions are based on ELN recommendations. For both ET and PV, first-line cytoreductive treatment may include hydroxyurea (HU) which is proven to lower thrombotic complications. Anagrelide is a viable second-line therapy in ET. In the PT-1 trial, HU’s superiority over anagrelide was demonstrated in in 809 ET patients at high risk for vascular events. Patients in the anagrelide group were significantly more likely to develop arterial thrombosis, serious hemorrhage and have transformation to MF with a decreased risk of venous thromboembolism. Conversely, the ANAHYDRET study evaluating 259 high-risk ET patients compared anagrelide with hydroxyurea (with the notable deletion of aspirin from the treatment plan) and did not identify any significant differences between groups in terms of arterial or venous thrombosis, severe bleeding events or rates of discontinuation.

In PV, non-leukomogenic pegylated interferon-2a (PEG-INF-2a; Pegasys) is an acceptable alternative to HU and has been documented to induce complete hematological response in 76% and 77% of patients with PV and ET, respectively, as well as result in decreases in JAK2 allele burden. Of note, genotypic contexts were found to influence clinical and molecular responses. Currently underway is a randomized, open-label trial through the MPD Research Consortium evaluating the
safety, toxicity and tolerability of PEG-INF-2a against HU in high-risk PV and ET patients (NCT01259856). A phase 3 randomized, controlled study comparing the efficacy and safety of the novel monopegylated interferon alpha-2b against HU in high-risk PV is also underway (PROUD-PV trial; NCT01949805).

For ET patients resistant or no longer a candidate for HU or anagrelide, other non-leukemogenic drugs (such as INF) may be utilized. Pipobroman is not used as first-line therapy given its leukemogenic potential as demonstrated in the French Polycythemia Study Group (FPSG) randomized study. It may be considered for patients over age 70 who are intolerant to the aforementioned options. Busulphan incurs similar risks and should be similarly restricted to older populations.

In MF, treatment of symptomatic anemia may include the use of corticosteroids, androgens, immunomodulatory agents (thalidomide, lenalidomide), erythropoiesis-stimulating agents and splenectomy. It should be mentioned that not all immunomodulatory demonstrate similar efficacy. A phase 3 study of pomalidomide vs. placebo in transfusion-dependent MF patients showed no significant differences in transfusion responses (16% [11-23%] versus 16% [8-26%]). Non-targeted cytoreductive treatments including hydroxyurea, cladribine, oral melphalan and busulphan have shown very modest clinical benefits for splenomegaly but may potentiate leukemic transformation with significant side-effect profiles. Non-pharmacological modalities such as radiotherapy or splenectomy are also available for select populations. Given the high mortality rate (5-10%) and considerable morbidity (47%), splenectomy is reserved patients with exceptionally large spleens or those failing pharmacological therapies.
**JAK2 Inhibition – Single Agent**

**Ruxolitinib**

Ruxolitinib is approved for MF in the United States, European Union and many other countries based on the two COMFORT studies where its effects on splenomegaly symptom improvement, and perhaps survival were successfully demonstrated. In a 3.5 year follow-up analysis of the COMFORT-II data, ruxolitinib was associated with a 42% reduction in risk of death (HR=0.58, 95% CI 0.36-0.93) in comparison to best available therapy (BAT). At 3.5 years, the probability of survival was 54% and 71% in BAT and ruxolitinib arms, respectively. Ruxolitinib has also been shown to promote weight gain (96% of subjects) and improve total cholesterol (97% of subjects) presumably via reversal of MF-related cachexia and catabolic pathways. It is currently under investigation for intermediate-1 disease MF patients in the phase 2 study, ROBUST.

Ruxolitinib has also been evaluated in ET and PV, with most activity seen in patients with PV. In a phase II study of 34 PV patients refractory or intolerant to HU receiving ruxolitinib for a median of 152 weeks, hematocrit levels <45% and non-palpable spleen measurements by 24 weeks were achieved in 97% and 44% of patients, respectively with significant improvement in symptoms. The RESPONSE trial is a randomized, phase 3 study which evaluated the use of ruxolitinib against BAT in PV patients resistant or intolerant to HU (NCT01243944). By week 32, 71.8% and 23.6% of ruxolitinib treated patients had a decrease in spleen size and complete hematological remission from baseline vs. 33% and 8.9%, respectively in the BAT arm. The RELIEF study (NCT01632904) is an ongoing randomized, double-blind study comparing symptoms in ruxolitinib-treated PV patients versus those receiving HU. Results on this trial have not yet been made publically available.
Other JAK2 Inhibitors

Numerous other JAK2 inhibitors exist in various stages of investigation (Figure 3), with 2 currently in phase III trials. Momelotinib (MMB; CYT387) has demonstrated efficacy in improving splenomegaly and MPN-related symptoms with the added benefit of reducing anemia. A phase ½ trial of high or intermediate-risk MF patients recently demonstrated anemia and spleen response rates of 59% and 48%, respectively. Forty-nine percent of RBC transfusion-dependent patients (one month prior to study entry) achieved transfusion-independence. However, grade 3/4 thrombocytopenia was noted in 32% of recipients. The drug is currently being evaluated against ruxolitinib in a 24-week double-blind, phase III study of primary or secondary intermediate and high-risk MF patients naïve to JAK2 inhibitor therapy (NCT01969838).

Pacritinib (SB1518) has proven efficacious in reducing splenomegaly and improving constitutional symptoms with limited provocation of cytopenias, particularly in patients with baseline thrombocytopenia. In a pooled study of 129 MF patients from the databases of two phase 1/2 clinical trials, pacritinib was evaluated specifically for its effects on patients with thrombocytopenia. Forty-three percent and 38% of patients with baseline platelet counts <100,000/uL and <50,000/uL, respectively, had a >/=35% reduction in spleen volume from baseline. Consistent with previous data, most adverse events were gastrointestinal related and mild. Forty-six percent of patients with baseline platelet counts </=100,000/uL showed no significant grade change in hemoglobin and platelet counts from baseline. The drug is currently under comparison to BAT in two phase 3 studies of MF patients without (PERSIST-1 [NCT01773187]) and with (PERSIST-II [NCT02055781]) baseline thrombocytopenia.

A number of JAK2 inhibitors have been removed from clinical trials secondary to toxicity (Figure 3). Fedratinib (SAR302503), an inhibitor of JAK2V617F, FLT3 and RET, was removed from clinical trials in November, 2013 as a result of neurological
complications including Wernicke’s encephalopathy. Its efficacy was however substantial in MF and documented in a phase 3 randomized, double-blind placebo-controlled study (JAKARTA). Similarly, CEP-701, XL019, LY278544, BMS-911543 and AZD 1480 have been removed from trial, secondary to myelosuppression, gastrointestinal toxicity, neurological effects, and/or insufficient activity.

Non JAK2 Targets and Combination Treatments

Recognizing that MPN disorders are the result of constitutive activation of the JAK-STAT signaling pathway with subsequent propagation of downstream mediators (STAT3/5, PI3K, MAPK), combination treatments targeting multiple levels of the signaling cascade become a rational intervention. As such, a variety of small-molecule novel therapies have been under parallel investigation with JAK2 inhibitors to emphasize synergistic biological activity and compensate for treatment-related adverse events such as anemia (Table 2).

The phosphatidylinositol 3-kinase (PI3K) pathway is of particular interest given its pleiotropic effects on cellular proliferation, metabolism and mediation of cellular drug resistance. PI3K inhibitor use, in combination with ruxolitinib, has demonstrated significant anti-proliferative activity suggesting that inhibition of JAK2 signaling plays an essential role in increasing sensitization of cells to PI3K inhibition. Mammalian target of Rapamycin (mTOR) similarly functions as a regulatory serine/threonine kinase important to cellular metabolism, apoptosis and proliferation. Use of mTOR inhibitors in singularity within MPN disorders has demonstrated modest results without impacting JAK2V617F mutational burden, likely reflecting the existence of alternative regulatory pathways. Their use as combination treatment with JAK2 inhibitors is under investigation.
Histone deacetylase inhibitors (HDACs; givinostat) are also a rational MPN therapy considering that histone deacytylase modulates a number of genes involved in cell cycle regulation, hematopoiesis, proliferation and apoptosis. An investigation using givinostat showed JAK2V617F positive cells to be two to three times more sensitive to givinostat-induced inhibition of colony formation, cellular proliferation and apoptosis induction than JAK2-wild type cells. HDAC inhibitors are currently under clinical investigation with ruxolitinib [NCT01693601 (USA); NCT01433445 (UK)]. The hedgehog signaling pathway is involved in cellular differentiation and proliferation in multiple stages of hematopoiesis, along with maintenance and homeostasis of cellular precursors. Their efficacy as single-agents has been documented in solid tumor malignancies and their role in MPN disorders remains under investigation (LDE-225; NCT01787552).

Antifibrotic agents function as endogenous proteins that respond to local tissue damage and stimulate macrophage and monocyte differentiation with subsequent prevention and reversal of fibrosis. In a phase 2 study of MF, the antifibrotic agent pentraxin (PTX-2) showed improvement in bone marrow fibrosis, cytopenias, symptoms and spleen size. Antifibrotic agents are presently being investigated with ruxolitinib in two clinical trials (NCT01369498; NCT01981850). Imetelstat, a potent inhibitor of telomerase that uniquely distributes specifically to bone marrow, has been shown to result in molecular remissions, hematological remissions and reverse bone marrow fibrosis. Side effects include myelosuppression with greatest toxicity observed in patients receiving upfront dosing and it is currently on hold for use in ET and PV due to liver toxicity. As previously noted, immunomodulatory agents have proven efficacious in the treatment of anemia and thrombocytopenia. Their use in combination with ruxolitinib is under active investigation (NCT01644110; NCT01375140).

The positive impact of JAK2 inhibitors on splenomegaly, symptoms, performance status and quality of life makes these therapies a logical adjunct to allo-SCT, particularly
as preconditioning. The use of ruxolitinib in allo-HSCT is currently under prospective investigation in two clinical trials (NCT01790295; NCT01795677).\textsuperscript{62,63} The JAK ALLO phase II study is assessing the impact of ruxolitinib in intermediate and high-risk MF candidates for HSCT. \textsuperscript{62} The study was briefly halted due to the development of tumor lysis syndrome and adverse events, but has resumed accrual based on interim analysis. A German allo-SCT trial similarly structured to the French study has demonstrated improvements in constitutional symptoms in 86% of patients receiving ruxolitinib at the time of transplantation, with 45% displaying a \(\geq 50\%\) reduction in spleen size.\textsuperscript{63} At present, JAK2 inhibition prior to allo-SCT remains experimental and is best done in the setting of a clinical trial such as the MPD-RC 114 trial (NCT01790295).

**How to Treat**

**PV and ET**

As previously discussed, in 2014 the management of PV and ET patients is primarily focused on prevention of thrombohemorrhagic complications and symptom management (Figure 5). In the future, we will perhaps have the molecular insight to choose medical therapies which can definitively prevent progression of MF or MPN-blast phase. At present, we recommend all PV and ET cases be assessed for prognosis by risk score (Table 1) and MPN symptom burden (MPN-10)\textsuperscript{21}, at the time of diagnosis. In our opinion, stratifying MPN symptom burden by MPN-10 quartile (MPN-10 Q1:<8; MPN-10 Q2: 8-17; MPN-10 Q3: 18-31; MPN-10 Q4: \(\geq 32\)) simplifies symptomatic groupings and allows for objective evaluation of symptomatic response. Further validation of this approach is ongoing.\textsuperscript{22} Per ELN recommendations, prevention of vascular events in PV is a crucial goal and is accomplished by controlling hematocrit levels to <45% and using
low dose aspirin. The role of aspirin in ET is unclear but may be beneficial in patients with microvascular complaints. Cardiovascular risk factors should be aggressively managed for both disorders including smoking cessation if applicable.

Selection of PV or ET patients needing cytoreductive therapy should incorporate both the MPN risk score and clinical scenario (ELN recommendations) such as intolerance of phlebotomy. In our opinion, low-risk patients not receiving cytoreductive therapy should be monitored for changes in symptom burden, vascular events or pathologic progression which, if present, might warrant additional therapy. Regular assessment with MPN-10 may be beneficial in determining which patients are symptomatically undermanaged. For both ET and PV, the presence of former or current vascular events automatically constitutes a high-risk disease profile and front-line cytoreductive therapy should be employed. In concordance with ELN recommendations, HU is first-line therapy for both disorders with anagrelide or INF as second-line options in ET and PV, respectively. Clinical trials may also be considered. In our opinion, high-risk patients who, despite receiving standard therapies, develop worsening symptom burdens, persistent vascular events, cytoreductive resistance or intolerance, should be considered for JAK2 inhibitor or INF trials with HU (if they have not previously received). Data from the randomized, phase III trials of ruxolitinib for PV may lead to FDA/EMA approval and provide a clear second-line therapy for PV patients, or for those on HU who have inadequately controlled symptoms.

MF

Management of MF patients requires initial evaluation of the risk score (choice of IPSS/DIPSS/DIPSS-Plus (when karyotype available)) and symptom burden (MPN-10). We believe management of DIPSS low-risk MF patients should be guided by symptomatology for the time being, and in the future perhaps by early disease altering
therapy (when shown definitely for either INF or new agents; Figure 4). It remains unclear whether patients who are low-risk by DIPSS but harbor high-risk molecular features should be managed differently (i.e. earlier choice for allogeneic transplant). Low-risk patients with low symptom burdens (symptom quartiles 1 and 2) may be observed or considered for a trial with interferon. Otherwise low-risk patients demonstrating higher symptom burdens (symptom quartiles 3 and 4) may be considered for ruxolitinib, JAK2 inhibitor trials or INF.

As per ELN recommendations, intermediate to high-risk patients, regardless of symptomatology, should be urgently assessed for allo-SCT candidacy. Patients deemed candidates may proceed with transplant and, in our opinion, be considered for JAK2 inhibitor trial prior. There is mounting evidence to support this approach in MPN-blast phase as well.\textsuperscript{64} For patients not deemed allo-SCT candidates or those in whom transplant may be delayed, it is our opinion that they initiate ruxolitinib or be considered for enrollment into a JAK2 inhibitor trial. In our experience, using current US labeling recommendations for the ruxolitinib starting dose may lead to anemia or thrombocytopenia in patients with compromised baseline values (i.e. hemoglobin <10g/dL regardless of platelet count). As such, we recommend a more modest starting dose of 10 mg twice daily for all patients with a hemoglobin <10g/dL and platelet counts >100,000 x 10\textsuperscript{9}/L and 5 mg twice daily for platelet counts between 50 – 100 x 10\textsuperscript{9}/L (ruxolitinib product label). Long term follow-up of the COMFORT I and II trials do suggest cytopenias from ruxolitinib use are worst during initial 3 months of therapy and that anemia, in particular, can improve after 6 months. Thus, it is best to avoid early dose reductions if the patient is stable from an anemia or thrombocytopenia standpoint. If cytopenias become problematic with JAK2 inhibitor therapy (or is not aided by JAK inhibitor therapy), one may consider many ongoing clinical trials that incorporate ruxolitinib plus a second agent to aid anemia (androgens, immunomodulatory drug,
hypomethylating agent, anti-fibrosing agent). In our opinion, patients non-responsive to JAK2 inhibitor therapy from a splenic or symptomatic standpoint (including patients with refractory cytopenias) should be considered for trials with other JAK2 inhibitors (in second line setting), ruxolitinib combination trials or clinical trials using non-JAK2 inhibitors.

**Conclusion:**

The past 10 years after the discovery of the JAK2-V617F mutation has led to unprecedented advances in our understanding of MPN biology, and many therapeutic innovations. Management of MPN patients has evolved to require a thoughtful and individualized approach which incorporates prognosis, disease burden, candidacy of allogeneic transplantation, assessment of comorbidities and the patients therapeutic goals. JAK inhibitors have made a meaningful impact as single agent therapies for MF, and now potentially problematic cases of PV. A broad array of ongoing trials will answer whether alternative pathways (HDAC, telomerase, hedgehog) alone or in combination with JAK inhibitors are more effective than JAK inhibition alone.

**Authorship**

HLG and RAM wrote the manuscript.

No conflicts of interest to declare.
References


Table 1. MPN Complication Rates, Prognosis and Risk Scoring Algorithms

<table>
<thead>
<tr>
<th></th>
<th>Essential Thrombocythemia</th>
<th>Polycythemia Vera</th>
<th>Primary Myelofibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombotic Events</td>
<td>10-29%^{23}</td>
<td>34-39%^{23}</td>
<td>7.2-13.2%^{65,66}</td>
</tr>
<tr>
<td>Bleeding Events</td>
<td>0.3%^{57}</td>
<td>2.9^{68}</td>
<td>-</td>
</tr>
<tr>
<td>Leukemic Transformation</td>
<td>2% at 15 years^{69,70}</td>
<td>5.5% at 15 years^{27}</td>
<td>6-18%^{71}</td>
</tr>
<tr>
<td>Overall Survival</td>
<td>14.7 years^{70}</td>
<td>6.5-24 years^{72,73}</td>
<td>6-10 years^{28,74,75}</td>
</tr>
<tr>
<td>Risk Algorithms</td>
<td>IPSET^{66}</td>
<td>Tefferi Criteria^{27}</td>
<td>DIPSS PLUS^{2}</td>
</tr>
<tr>
<td>Age</td>
<td>≥ 60 (2 pts) vs. &lt; 60</td>
<td>≥67 (5 pts) 57-66 (2 pts)</td>
<td>≥65 (1 pt) vs. &lt;65</td>
</tr>
<tr>
<td>Leukocytes</td>
<td>≥ 11 (1 pt) vs. &lt;11 x 10^9/L</td>
<td>≥15 (1 pt) vs. &lt;15 x 10^9/L</td>
<td>&gt;25 (1 pt) vs. ≤25 x 10^9/L</td>
</tr>
<tr>
<td>Prior Vascular Events</td>
<td>Yes (1 pt) vs. No</td>
<td>Yes (1 pt) vs. No</td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>&lt;10 (2 pts) vs. ≥10g/dL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constitutional Symptoms</td>
<td>Present (1 pt) vs. Absent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral Blood Blasts</td>
<td>≥1% (1pt) vs. &lt;1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unfavorable Karyotype</td>
<td>Present (1 pt) vs. Absent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Red Blood Cell Transfusion Requirement</td>
<td>Present (1 pt) vs. Absent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platelet Count &lt;100,000 x 10^9/L</td>
<td>Present (1 pt) vs. Absent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High Risk</td>
<td>3-4 points</td>
<td>4 points</td>
<td>&gt;4 points</td>
</tr>
<tr>
<td>Intermediate 2 Risk</td>
<td>N/A</td>
<td>3 points</td>
<td>3-4 points</td>
</tr>
<tr>
<td>Intermediate 1 Risk</td>
<td>1-2 points</td>
<td>1-2 points</td>
<td>1-2 points</td>
</tr>
<tr>
<td>Low Risk</td>
<td>0</td>
<td>0 points</td>
<td>0 points</td>
</tr>
</tbody>
</table>

# - Constitutional symptoms were defined as weight loss over 6 months, night sweats, unexplained fever^{29}
Table 2. Current JAK Inhibitor Clinical Trials for Patients with a Myeloproliferative Neoplasm

<table>
<thead>
<tr>
<th>JAK Inhibitor (Target(s))</th>
<th>Second Agent</th>
<th>Class Second Agent</th>
<th>Disease</th>
<th>Trial Number (clinicaltrials.gov)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pacritinib (JAK2, FLT3)</td>
<td>N/A</td>
<td>N/A</td>
<td>MF</td>
<td>NCT01773187</td>
</tr>
<tr>
<td>Momelotinib (JAK1, JAK2)</td>
<td>N/A</td>
<td>N/A</td>
<td>MF, PV, ET</td>
<td>NCT01969838 (MF) NCT01998828 (PV and ET)</td>
</tr>
<tr>
<td>NS-018 (JAK2)</td>
<td>N/A</td>
<td>N/A</td>
<td>MF</td>
<td>NCT01423851</td>
</tr>
<tr>
<td>INC-039110 (JAK1)</td>
<td>N/A</td>
<td>N/A</td>
<td>MF</td>
<td>NCT01633372</td>
</tr>
</tbody>
</table>

| Ruxolitinib | Danazol | Androgen | MF | NCT01732445 |
| Ruxolitinib | Pomalidomide | IMID | MF | NCT01644110 |
| Ruxolitinib | Lenalidomide | IMID | MF | NCT01375140 |
| Ruxolitinib | Azacitidine | Hypomethylation | MF | NCT01787487 |

| Ruxolitinib | Panobinostat | HDAC Inhibitor | MF | NCT01693601 (USA) NCT01433445 (UK) |
| Ruxolitinib | GS-6624 | Anti-fibrosing | MF | NCT01369498 |
| Ruxolitinib | PRM-151 | Anti-fibrosing | MF | NCT01981850 |
| Ruxolitinib | BKM-120 | PI3-Kinase Inhibitor | MF | NCT01730248 |
| Ruxolitinib | LDE-225 | Hedgehog Inhibitor | MF | NCT01787552 |
| Ruxolitinib (MPD-RC Trial) | Allogeneic Transplant | N/A | MF | NCT01790295 |
| Ruxolitinib (GOELAMS Trial - France) | Allogeneic Transplant | N/A | MF | NCT01795677 |
Figure Legends:

**Figure 1.** MPN Symptoms by Subtype

**Figure 2.** Panel A. Mean Symptom Severity by Subtype, Panel B. Symptom Prevalence by MPN Subtype

**Figure 3.** Therapeutic Efficacy of JAK Inhibitors

**Figure 4** Proposed algorithm of Therapy for MF in 2014

**Figure 5.** Proposed algorithm of Therapy for ET/PV in 2014
<table>
<thead>
<tr>
<th>Symptom</th>
<th>ET (n=874)</th>
<th>PV (n=729)</th>
<th>MF (n=486)</th>
<th>Total (n=2089)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>Incidence (%)*</td>
<td>Mean (SD)</td>
<td>Incidence (%)*</td>
</tr>
<tr>
<td>Worst fatigue (one-item BFI)</td>
<td>3.9 (2.9)</td>
<td>84</td>
<td>4.2 (2.9)</td>
<td>85</td>
</tr>
<tr>
<td>Early satiety</td>
<td>2.1 (2.6)</td>
<td>56</td>
<td>2.4 (2.7)</td>
<td>60</td>
</tr>
<tr>
<td>Abdominal discomfort</td>
<td>1.6 (2.3)</td>
<td>48</td>
<td>1.6 (2.3)</td>
<td>48</td>
</tr>
<tr>
<td>Inactivity</td>
<td>1.9 (2.5)</td>
<td>54</td>
<td>2.4 (2.8)</td>
<td>60</td>
</tr>
<tr>
<td>Concentration</td>
<td>2.2 (2.7)</td>
<td>58</td>
<td>2.6 (2.8)</td>
<td>62</td>
</tr>
<tr>
<td>Night sweats</td>
<td>1.9 (2.7)</td>
<td>47</td>
<td>2.1 (2.8)</td>
<td>52</td>
</tr>
<tr>
<td>Itching</td>
<td>1.7 (2.6)</td>
<td>46</td>
<td>2.7 (3.1)</td>
<td>62</td>
</tr>
<tr>
<td>Bone pain</td>
<td>1.7 (2.6)</td>
<td>45</td>
<td>2.0 (2.8)</td>
<td>48</td>
</tr>
<tr>
<td>Fever</td>
<td>0.4 (1.2)</td>
<td>17</td>
<td>0.4 (1.2)</td>
<td>19</td>
</tr>
<tr>
<td>Weight loss</td>
<td>0.9 (2.0)</td>
<td>28</td>
<td>1.2 (2.2)</td>
<td>33</td>
</tr>
<tr>
<td>MPN - 10</td>
<td>18.3 (15.4)</td>
<td>---</td>
<td>21.6 (16.7)</td>
<td>---</td>
</tr>
</tbody>
</table>

ET, essential thrombocythemia; MF, myelofibrosis; PV, polycythemia vera
**FIGURE 3**

<table>
<thead>
<tr>
<th>Status</th>
<th>Agent</th>
<th>Myelofibrosis</th>
<th>Polycythemia Vera</th>
<th>Essential Thrombocythemia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Spleen</td>
<td>Const. Sympt.</td>
<td>HB</td>
</tr>
<tr>
<td>Approved (MF) Phase III (PV)</td>
<td>Ruxolitinib (INCB18424)</td>
<td>+++</td>
<td>+++</td>
<td>_</td>
</tr>
<tr>
<td>Phase III (MF)</td>
<td>Pacritinib- (SB1518)</td>
<td>+++</td>
<td>+++</td>
<td>_</td>
</tr>
<tr>
<td>Phase III (MF) Phase II (PV/ET)</td>
<td>Momelotinib (CYT387)</td>
<td>+++</td>
<td>+++</td>
<td>_</td>
</tr>
<tr>
<td>Phase III (MF) ON HOLD</td>
<td>Fedratinib (SAR302503)</td>
<td>+++</td>
<td>+++</td>
<td>_</td>
</tr>
<tr>
<td>Phase II (MF)</td>
<td>NS-018</td>
<td>+++</td>
<td>+++</td>
<td>Unk</td>
</tr>
<tr>
<td>Phase II (MF)</td>
<td>INCB039110 (JAK1 Alone)</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
</tr>
</tbody>
</table>

Const. Sympt, Symptoms; HB, Hemoglobin; Phleb, Phlebotomy Numbers; SURV, Survival; Vasc events, Thrombosis/Bleeding; Unk, unknown
Proposed Algorithm of Therapy of MF in 2014

**Diagnosis of MF (Primary, Post ET or Post PV Myelofibrosis)**

**Calculate DIPSS MF Score & Assess MPN Symptoms (MPN 10)**

---

**Symptom Quartiles by MPN 10**

- **Q1**: TSS < 8
- **Q2**: TSS 8-17
- **Q3**: TSS 18-31
- **Q4**: TSS ≥32

---

**Low Risk**

- Med S = 185m
- **Symptom**: Q1-Q2

**Low Risk**

- Med S < 185m
- **Symptom**: Q3-Q4

**Intermediate to High Risk**

- Med S = 16m (H), 35m (Int. 2), 78 (Int. 1)

**Assess role and timing of ALLO SCT (Donor, Risk, Candidate)**

**ALLO – Urgent, Delayed, Never**

---

**JAK2 Inhibitors**

- Ruxolitinib (Jakifi/Jakivi)
  - Approved for MF
- Clinical Trial JAK2 Inhibitor
  - (See Figure 2)

**Anemia Rx**

- Clinical Trials
- IMID/Androgens/EPO
- Splenectomy

---

**N.B.**

Consider Rx for Prevention of Vascular Events in Appropriate Patients (Aspirin & Cytoreduction)

---

**Possible Role Of JAK2 Inhib. (Trial) or INF (Trial)**

**Observation Vs. INF (Trial)**

**Possible Role Of JAK2 Inhib. Prior (Trial)**

**Proceed to ALLO (Possible JAK2 Inhib. Prior) (Trial)**

**JAK2 Inhibitor**

*Unless anemia/cytopenias main problem*

---

**JAK2 Single Agent Failure Refractory Cytopenias**

**Clinical Trials**

- Ruxo Combination
- Non Ruxo JAK2
- New Targets

---

**FIGURE 4**
Proposed Algorithm of Therapy of ET/PV in 2014

**Assess Symptom Quartile by MPN 10**
- Q1: TSS < 8
- Q2: TSS 8-17
- Q3: TSS 18-31
- Q4: TSS ≥ 32

**Diagnosis of PV or ET**

- Assess MPN Risk Score (Table 1) & Assess MPN Symptoms (MPN 10)
- Control of Hematocrit (<45%) in PV (? In ET)
- Low dose aspirin in appropriate patients

**JAK2 Inhibitor (Experimental Indication)**
- Ruxolitinib (Jakifi/ Jakivi)
- Other Clinical Trial JAK2 Inhibitor

**Front Line Cytoreduction**
- HU, or HU vs INF Clinical Trial

**Consider JAK2 Inhibitor (Trial) or INF (Trial)/HU if not previously received**

**FIGURE 5**
Therapy for myeloproliferative neoplasms: when, which agent and how?

Holly L. Geyer and Ruben A. Mesa